b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29738261</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>09</Month>\n            <Day>30</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>09</Month>\n            <Day>30</Day>\n        </DateRevised>\n        <Article PubModel="Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1735-3947</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>21</Volume>\n                    <Issue>5</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>05</Month>\n                        <Day>01</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Archives of Iranian medicine</Title>\n                <ISOAbbreviation>Arch Iran Med</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>The Significance of the Stromal Response in Breast Cancer: An Immunohistochemical Study of Myofibroblasts in Primary and Metastatic Breast Cancer.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>185-190</MedlinePgn>\n            </Pagination>\n            <Abstract>\n                <AbstractText Label="BACKGROUND">Gene expression profiling of breast cancer has demonstrated the importance of stromal response in determining the prognosis of invasive breast cancer. The host response to breast cancer is of increasing interest to pathologists and may be a future focus for novel pharmacological treatments.</AbstractText>\n                <AbstractText Label="METHODS">This study describes the pattern of distribution of stromal myofibroblasts using immunostains for CD10 and smooth muscle actin (SMA) in 50 primary breast cancers and their matched nodal metastases (68.6% nodes positive and 31.4% nodes negative). The stroma within the tumor (intratumoral) and at the advancing tumor edge (peri-tumoral) was studied in both primary and nodal sites. A simple quantitative scoring system was employed for both immunostains. The correlation between expression of these markers by stromal cells and standard pathological prognostic factors of stage, grade, hormone receptor and Her-2 status was analysed.</AbstractText>\n                <AbstractText Label="RESULTS">SMA-positive stromal cells were more abundant in peri-tumoral stroma compared with intratumoral stroma in both primary and metastatic lesions. SMA expression in the lymph node metastases showed a significant correlation with tumor stage. SMA expression in peri-tumoral stroma correlated with Her-2 status.</AbstractText>\n                <AbstractText Label="CONCLUSION">The results of this study suggest that myofibroblasts, particularly those expressing SMA, might potentiate the progression of the carcinomatous process especially in nodal metastases. Thus these cells may be a potential therapeutic target.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2018 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Roozdar</LastName>\n                    <ForeName>Alale</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pathology and Stem Cells Research Center, Pathology Department, Afzalipour Kerman Medical Sciences University, Kerman, Iran.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hayes</LastName>\n                    <ForeName>Malcolm M</ForeName>\n                    <Initials>MM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pathology Department, B.C. Cancer Agency, University of British Columbia, Vancouver, Canada.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pourseyedei</LastName>\n                    <ForeName>Bahram</ForeName>\n                    <Initials>B</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Surgery Department, Afzalipour Kerman Medical Sciences University, Kerman, Iran.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zeinalinejad</LastName>\n                    <ForeName>Hamid</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Surgery Department, Afzalipour Kerman Medical Sciences University, Kerman, Iran.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Shamsi Meymandi</LastName>\n                    <ForeName>Manzumeh</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pathology and Stem Cells Research Center, Pathology Department, Afzalipour Kerman Medical Sciences University, Kerman, Iran.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Dabiri</LastName>\n                    <ForeName>Bahram</ForeName>\n                    <Initials>B</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pathology and Stem Cells Research Center, Pathology Department, Afzalipour Kerman Medical Sciences University, Kerman, Iran.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Dabiri</LastName>\n                    <ForeName>Shahriar</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pathology and Stem Cells Research Center, Pathology Department, Afzalipour Kerman Medical Sciences University, Kerman, Iran.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>05</Month>\n                <Day>01</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Iran</Country>\n            <MedlineTA>Arch Iran Med</MedlineTA>\n            <NlmUniqueID>100889644</NlmUniqueID>\n            <ISSNLinking>1029-2977</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D018952">Antigens, CD34</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.10.1</RegistryNumber>\n                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.10.1</RegistryNumber>\n                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018952" MajorTopicYN="N">Antigens, CD34</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001940" MajorTopicYN="N">Breast</DescriptorName>\n                <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D058628" MajorTopicYN="N">Myofibroblasts</DescriptorName>\n                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Breast cancer</Keyword>\n            <Keyword MajorTopicYN="Y">Metastatic breast cancer</Keyword>\n            <Keyword MajorTopicYN="Y">Myofibroblast</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2016</Year>\n                <Month>04</Month>\n                <Day>18</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>04</Month>\n                <Day>08</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>5</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>5</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>1</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>epublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29738261</ArticleId>\n            <ArticleId IdType="pii">S1029-2977-21(05)185-0</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'